Metabolic shifts in plasma amino acids and related metabolites in response to SGLT2 inhibition and hyperglycemia in type 1 diabetes
Abstract
Regulated kidney function is dependent on maintaining efficient energy utilization. Our aim in this study was to determine the effects of acute, ambient hyperglycemia and sodium-glucose cotransporter-2 (SGLT2) inhibition on plasma amino acid metabolism in patients with type 1 diabetes (T1D). The ATIRMA trial, a single-arm study, evaluated the effects of 8 weeks of oral empagliflozin (25 mg/day) in 40 young adults with T1D. The study involved consecutive two-day assessments of clamped euglycemia and hyperglycemia at both baseline and post-treatment. MetaboAnalyst 6.0 categorized 35 metabolites into significant pathways, which were statistically compared using principal component analysis. Acute hyperglycemia induced changes to 10 metabolic pathways, including but not limited to increases in cysteine and methionine metabolism (0.52 ± 0.12, p < 0.0001), valine, leucine, and isoleucine biosynthesis (0.31 ± 0.10, p = 0.002); and nitrogen metabolism (0.11 ± 0.03, p = 0.003). Introduction of empagliflozin was associated with a decrease in adenine, and an increase in cysteine and methionine metabolism (0.31 ± 0.13, p = 0.02) when maintained under euglycemia and a decrease in nitrogen metabolism under hyperglycemia (-0.07 ± 0.04, p = 0.04). Our findings show that SGLT2 inhibition counteracts the hyperglycemia-induced changes in plasma amino acid metabolism, potentially improving energy efficiency and metabolic health, though more research is needed to confirm these metabolic effects.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.